Chief Executive Officer
CurrentFlerie has since 2011 helped build >30 portfolio companies and had three successful exits in the life science sector. We invest in product development and commercial growth companies with a predominant focus on the biotechnology and pharmaceutical sector. Flerie became a publicly listed investment company on the Nasdaq Stockholm in June 2024.